20 YEARS OF EXCELLENCE IN INTERNATIONAL MEETINGS
alliedacademies.com
Joint Event on

2nd International Conference on
CELL AND GENE THERAPY
&
2nd World Congress on
PUBLIC HEALTH, EPIDEMIOLOGY AND NUTRITION
April 15-16, 2019 | Milan, Italy

Theresa A Deisher, Arch Gen Intern Med 2019, Volume 3
DOI: 10.4066/2591-7951-C2-025



Theresa A Deisher

AVM Biotechnology, USA

BIOGRAPHY

Theresa A Deisher obtained her PhD in Molecular and Cellular Physiology from Stanford University School of Medicine, USA. She is an expert in adult stem cell research and she is the first person to discover adult pluripotent stem cells. She is an inventor of over 35 issued US/Japan patents, whose discoveries have led to clinical trials of fibroblast growth factor 18 for osteoarthritis and cartilage repair and for Factor XIII for surgical bleeding. Prior to founding AVM Biotechnology, she worked at leading biotechnology companies including Genentech, Repligen, ZymoGenetics, Immunex and Amgen as their principal scientist and R&D Vice President. She had an extensive scientific and management experience in the commercial biotechnology field. She is a frequent lecturer on stem cell issues and an active member of ASH (The American Society of Hematology) and ASCO (American Society of Clinical Oncology).

tdeisher@avmbiotech.com

Note:

A NOVEL LYMPHOABLATION PRECONDITIONING AGENT (AVM0703) VIA RECEPTOR MEDIATED INDUCTION OF APOPTOSIS TO REDUCE PATIENT TOXICITIES PRIOR TO CART THERAPY OR STEM CELL TRANSPLANTS TO REDUCE TOXICITIES AND IMPROVE PATIENT SAFETY

Chemotherapy preconditioning prior to CART cells has been strongly associated with CRS, neurotoxicity, patient death and in some instances, has led to clinical trials being put on hold. There is an urgent need to develop a non-toxic and safe agent that lympho-ablates similar to chemotherapy. AVM0703 lympho-ablates both T and B lymphocytes for 'immune reset' via receptor mediated induction of caspase dependent apoptosis, sparing neutrophils, platelets, RBCs and stem cells. AVM0703 preconditioning will expand the number of patients eligible for CART therapy to include those too frail to tolerate chemotherapy preconditioning and will reduce the toxicities both medical and financial of chemotherapy or biologics based lymphoablation. HSC based gene therapy holds promise as a cure for many inherited primary immune deficiencies such as sickle cell disease, cerebral adrenoleukodystrophy, cystinosis, epidermolysis bullosa, hemophilia, enzyme replacements disorders, cystic fibrosis and muscular dystrophies. The toxicities of required chemotherapy preconditioning limit the number of people who choose HSCGT. A rela-

tively non-toxic lymphoablating small molecule such as AVM0703 will expand the opportunity for HSCGT. Spontaneous lymphocyte recovery is observed within 14 days. AVM0703 enhances the efficacy of autologous concentrated intra-articular bone marrow injections to treat knee arthritis, accelerates G-CSF-mediated mobilization of HSC into peripheral blood and dramatically enhances CART efficacy against melanoma. AVM0703 is being developed as a replacement for chemotherapy preconditioning (PC) required before allogeneic stem cell transplant (allo Tx), Autologous Hematopoietic Stem Cell Based Gene Therapy (AHSCGT) or Adoptive Cell Therapy (ACT). AVM0703 is being developed as a stand-alone treatment for direct apoptotic killing of relapsed/refractory lymphocytic leukemia, lymphoma and multiple myeloma and for residual HIV and steroid-resistant GvHD.

Note: